Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 8Colorectal Neoplasms 7Carcinoma, Hepatocellular 7Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 5Rectal Neoplasms 4Glioma 4Breast Neoplasms 4Neoplasms 3Meningeal Carcinomatosis 3Lung Neoplasms 3Colonic Neoplasms 3Ovarian Neoplasms 2Melanoma 2Hypertension 2Carcinoma, Renal Cell 2Breast Neoplasms, Male 2Uveal Melanoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neoplasms, Nerve Tissue 1Neoplasm Metastasis 1Multi-organ Metastatic Colorectal Cancer 1Liver Neoplasms 1Fallopian Tube Neoplasms 1Central Nervous System Neoplasms 1Biliary Tract Neoplasms 1Advanced Non-squamous Non-Small Cell Lung Cancer 1

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Neoplasms, Nerve Tissue × Bevacizumab × Clear all
NCT04446416 2026-04-09

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

NaviFUS Corporation

Phase NA Completed
6 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡